Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 318
- Registration Number
- NCT00848081
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
- Conditions
- Bipolar Depression
- Interventions
- Drug: Olanzapine Fluoxetine Combination (OFC)Drug: Placebo
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 291
- Registration Number
- NCT00844857
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yaroslavl, Russian Federation
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
- Conditions
- Colon CancerRectal Cancer
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4
- Registration Number
- NCT00845039
- Locations
- 🇺🇸
ImClone Investigational Site, Scranton, Pennsylvania, United States
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PlaceboDrug: LY451395
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT00843518
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waukesha, Wisconsin, United States
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 227
- Registration Number
- NCT00840034
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study for Participants With Pancreatic Cancer
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 157
- Registration Number
- NCT00839332
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
A Safety Study of LY2811376 Single Doses in Healthy Subjects
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: LY2811376Drug: Placebo
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 61
- Registration Number
- NCT00838084
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States
An Open Label Extension Study in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: LY2127399
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 182
- Registration Number
- NCT00837811
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Targu-Mures, Romania
Effect of Tadalafil Once a Day in Men With Erectile Dysfunction
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2011-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 217
- Registration Number
- NCT00836693
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Majadahonda, Spain
Study of IMC-11F8 in Participants With Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 44
- Registration Number
- NCT00835185
- Locations
- 🇪🇸
ImClone Investigational Site, Valencia, Spain